L&K Bio Subsidiary Reaches Settlement in Trade Secret Infringement Lawsuit with US Competitor

Spinal implant company L&K Biomed announced on the 22nd that it has reached a settlement in the trade secret infringement lawsuit between its subsidiary Aegis Spine and the U.S. company Life Spine.

L&K Biomed has resolved the litigation risk, which was considered its biggest obstacle, all at once, enabling it to expect increased sales through aggressive marketing in the U.S., which accounts for 70% of the entire spinal implant market.

Life Spine filed the lawsuit claiming that Aegis Spine infringed on its trade secrets related to its height-expandable spinal implant product 'ProLift,' and that based on this, the parent company L&K Biomed developed the 'XcellFix-XT.'

L&K Biomed independently developed the next-generation height-expandable spinal implant product 'PassLock-TM,' reflecting the latest global trends in minimally invasive surgery, and received approval from the U.S. FDA in March last year. It has recorded over 500 surgical cases.

PassLock-TM is a posterior and posterolateral insertion type, which is the most frequently performed procedure, and can adjust height up to 20 degrees. Minimizing the incision site during surgery reduces risks such as excessive bleeding and infection. It helps not only doctors but also patients recover quickly after surgery, resulting in high patient satisfaction.

An L&K Biomed official stated, "Although sales of the existing XcellFix-XT in the U.S. are difficult, we will strengthen sales in the European market with European CE certification," adding, "We will simultaneously achieve increased sales and improved profitability to leap forward as a global major spinal implant company."

This content was produced with the assistance of AI translation services.